Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.53
+4.8%		$2.87
$1.25
▼
$5.48
$153.52M2.92164,702 shs249,502 shs
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
$18.99
$18.99
$7.01
▼
$19.30
$655.69MN/A205,753 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%-50.65%-55.91%-48.66%-50.32%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.53
+4.8%		$2.87
$1.25
▼
$5.48
$153.52M2.92164,702 shs249,502 shs
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
$18.99
$18.99
$7.01
▼
$19.30
$655.69MN/A205,753 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%-50.65%-55.91%-48.66%-50.32%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
2.29
Hold$5.46256.86% Upside
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLLS and OSIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Underweight$9.00 ➝ $1.30
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$10.00 ➝ $8.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$4.00 ➝ $3.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
7/17/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$56.58M2.71N/AN/A$0.76 per share2.01
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$67.59M-$0.65N/AN/AN/A-102.34%-94.19%-21.34%11/13/2026 (Estimated)
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest CLLS and OSIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026H1 2026
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.2630-$0.22+$0.0430-$0.22$11.05 million$6.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
1.61
1.37
1.37
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.28%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
43.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
229100.34 million83.87 millionOptionable
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
34234.53 millionN/ANot Optionable

Recent News About These Companies

Osiris Chairman responds to column
December 24, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/osiris-chairman-responds-to-column
Stem Cell Market to Reach US$ 50.7 Billion by 2032, Growing at 10.7% CAGR Fueled by Advancements in Regenerative Medicine and Cell-Based Therapies
July 16, 2025  |  taiwannews.com.twT
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy
March 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ryoncil-first-fda-approved-mesenchymal-155711761.html?fr=sycsrp_catchall
Global Medical Disposables Market to be worth USD 326.4 Billion by 2033, Reveals Future Market Insights
December 18, 2024  |  fmiblog.comF
Human Osteoblasts Market Projected to Reach USD 85.3 Million by 2034 at a 6.4% of CAGR
October 31, 2024  |  fmiblog.comF
Global Medical Disposables Market to Reach USD 326…
October 24, 2024  |  pharmiweb.comP
Global Regenerative Medicine Market to Reach $472.95 Billion by 2032 | 25.86% CAGR
October 3, 2024  |  taiwannews.com.twT
Wound Care Biologics Market Future Looks Bright for Market Size with Soaring Projections
September 23, 2024  |  taiwannews.com.twT
Smith & Nephew buys Osiris in regenerative medicine push
July 25, 2024  |  pharmaphorum.comP
Type 1 Diabetes Drugs Market Revenue, Price, Growth Rate, Forecast To 2032
July 19, 2024  |  taiwannews.com.twT
Active Wound Care Market to Grow at 5.5% CAGR Through 2032 Amid Rising Chronic Wound Cases
May 29, 2024  |  pharmiweb.comP
Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%
May 25, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/global-topical-wound-agents-market-200000042.html
Cell and Gene Therapy Market Power of Anticipation Preparing for the Future of Market Size
May 2, 2024  |  taiwannews.com.twT
Tissue Engineering and Regeneration Market [2028]: Navigating Opportunities and Challenges
April 24, 2024  |  informazione.itI
Knee Cartilage Repair Market Growth Analysis, Size, Prominent Players, Overview, and Forecast 2024 to 2032
April 19, 2024  |  taiwannews.com.twT
Knee Cartilage Repair Market Size, Share, Growth Statistics, Latest Trends, and Forecast 2024 to 2032
April 12, 2024  |  taiwannews.com.twT
Global Anti-Biofilm Wound Dressing Market Projected to Witness Significant Growth US$ 1939.45 million by 2033
April 8, 2024  |  fmiblog.comF
Kanak Kanti
March 19, 2024  |  fool.comhttps://www.fool.com/author/5219/
Arnold Caplan, biologist who studied cells, dies at 82
February 11, 2024  |  cleveland.comC
Tissue Engineering Market Set to Soar Past USD 32.45 Billion by 2030
February 2, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tissue-engineering-market-set-soar-153000091.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.53 +0.07 (+4.79%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.53 0.00 (0.00%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Osiris Therapeutics stock logo

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)
As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas